Invention Grant
- Patent Title: Modulation of BCL11A for treatment of hemoglobinopathies
-
Application No.: US14987219Application Date: 2016-01-04
-
Publication No.: US09885041B2Publication Date: 2018-02-06
- Inventor: Stuart H. Orkin , Vijay G. Sankaran
- Applicant: CHILDREN'S MEDICAL CENTER CORPORATION , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- Applicant Address: US MA Boston US MA Cambridge
- Assignee: The Children's Medical Center Corporation,President and Fellows of Harvard College
- Current Assignee: The Children's Medical Center Corporation,President and Fellows of Harvard College
- Current Assignee Address: US MA Boston US MA Cambridge
- Agency: Nixon Peabody LLP
- Agent Davis S. Resnick; Tari W. Mills
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; A61K31/70 ; C12N5/00 ; C12N15/113 ; A61K31/713 ; A01K67/027 ; C07K14/47 ; C07K14/805 ; C12N15/85 ; C12N15/86 ; A61K35/28 ; A61K49/00 ; C12N5/0789 ; C12Q1/68
Abstract:
The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
Public/Granted literature
- US20170152513A1 MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES Public/Granted day:2017-06-01
Information query
